Bicara Therapeutics Inc. Logo

Bicara Therapeutics Inc.

Developing first-in-class, dual-action bifunctional therapies for solid tumor patients.

BCAX | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
116 HUNTINGTON AVENUE SUITE 703, 2116 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class bifunctional therapies for patients with solid tumors. The company engineers advanced biologics designed to combine the precision of a validated tumor-targeting agent with the power of a tumor microenvironment modulator. This dual-action approach aims to deliver more effective and durable anti-tumor responses. Bicara's pipeline is dedicated to advancing these innovative targeted treatments to address significant unmet needs in oncology, with a focus on indications such as head and neck cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Bicara Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Bicara Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Bicara Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany
FYB
Fortress Biotech, Inc. Logo
Acquires, develops, and commercializes drugs for oncology, gene therapy, and rare diseases.
United States of America
FBIO
FRACTYL HEALTH, INC. Logo
Developing gut-targeted endoscopic and gene therapies for obesity and type 2 diabetes.
United States of America
GUTS
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy
FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan
4554
Fulcrum Therapeutics, Inc. Logo
Develops gene-modulating small molecule drugs for rare, genetically defined diseases.
United States of America
FULC
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan
4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea
220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea
341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea
456160

Talk to a Data Expert

Have a question? We'll get back to you promptly.